- EDIT: Crizotinib (tradename is Xalkori) from Pfizer $PFE was approved Friday 8/26/11 by the FDA - click here for press release.
- Here are my quick notes from the Synta Pharma presentation at the Canaccord Genuity conference on 8/11/2011. As always, more detailed information and resources can be found on the full SNTA research page.
- Note that portions of the discussion overlap with that of the recent 2q11 earnings conference call on 8/4/11 - click here for my notes from that webcast.
- My complete notes are below the jump:
We all know that it has been a rough month or two for the biotech sector, fueled by the overall market decline following the debt ceiling debate as well as the biotech sector weakness following $DNDN Dendreon's weak Provenge prostate cancer vaccine sales and resulting 70% drop in stock value. This has resulted in a large list of biotech companies trading at extremely low valuations. While I can't promise that prices won't continue lower, I think now is the time for careful research and evaluation on stocks you may want to own in the coming months. I feel some of the companies listed below are worth owning at today's prices (8/23/11), others may decline even further. For full disclosure, click here for a current list of which stocks I own among those I cover. As always, complete your own research and consider your circumstances before taking any action based on my thoughts.
Keep reading below the jump for my stock by stock analysis: